Global Osteoporosis Drugs Market Size, Share, Trend, Analysis and Forecast 2026 | TechSci Research

1
2016 2026
GLOBAL OSTEOPOROSIS DRUGS MARKET FORECAST
OPPORTUNITIES
2

• Scope of Report
• Product of Interest (POI) Osteoporosis Drugs

Osteoporosis drugs are grouped into two
categories Antiresorptive drugs slow the rate
that your body breaks down bone. They include
bisphosphonates, denosumab, estrogens,
calcitonin, and others. Anabolic drugs increase
bone formation. Examples are romosozumab
(Evenity) and teriparatide (Forteo).
Market Segmentation
ROUTE OF ADMINISTRATION
DRUG CLASS

• Branded
• Bisphosphonates
• Selective Estrogen Inhibitors Modulator (SERM)
• Parathyroid Hormone Therapy
• Calcitonin
• Rank Ligand Inhibitors
• Others
• Generics

• Oral
• Injectable
• Others

OSTEOPOROSIS DISEASE TYPE

• Primary Osteoporosis
• Secondary Osteoporosis

DISTRIBUTION CHANNEL

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

3

• Table of Contents

S. No. Contents Contents Contents Contents Page No.
1. Product Overview (Definition of Product Type and major terminologies used in the report) Product Overview (Definition of Product Type and major terminologies used in the report) Product Overview (Definition of Product Type and major terminologies used in the report) Product Overview (Definition of Product Type and major terminologies used in the report)
2. Research Methodology (Detailed description of the methodology used to conduct the research, Raw data backup, list of all secondary sources, List of respondents for primary surveys) Research Methodology (Detailed description of the methodology used to conduct the research, Raw data backup, list of all secondary sources, List of respondents for primary surveys) Research Methodology (Detailed description of the methodology used to conduct the research, Raw data backup, list of all secondary sources, List of respondents for primary surveys) Research Methodology (Detailed description of the methodology used to conduct the research, Raw data backup, list of all secondary sources, List of respondents for primary surveys)
3. Impact of COVID-19 on Global Osteoporosis Drugs Market Impact of COVID-19 on Global Osteoporosis Drugs Market Impact of COVID-19 on Global Osteoporosis Drugs Market Impact of COVID-19 on Global Osteoporosis Drugs Market
4. Executive Summary (This chapter covers summary of the complete study.) Executive Summary (This chapter covers summary of the complete study.) Executive Summary (This chapter covers summary of the complete study.) Executive Summary (This chapter covers summary of the complete study.)
5. Voice Of Customer Voice Of Customer Voice Of Customer Voice Of Customer
6. Global Osteoporosis Drugs Market Outlook, 2016-2026F (This chapter includes a brief overview of the product of interest market such as total markets growth rate, expected growth rate, key growth levers, leading region, top grossing product types, etc. It includes more of a qualitative information about the market.) Global Osteoporosis Drugs Market Outlook, 2016-2026F (This chapter includes a brief overview of the product of interest market such as total markets growth rate, expected growth rate, key growth levers, leading region, top grossing product types, etc. It includes more of a qualitative information about the market.) Global Osteoporosis Drugs Market Outlook, 2016-2026F (This chapter includes a brief overview of the product of interest market such as total markets growth rate, expected growth rate, key growth levers, leading region, top grossing product types, etc. It includes more of a qualitative information about the market.) Global Osteoporosis Drugs Market Outlook, 2016-2026F (This chapter includes a brief overview of the product of interest market such as total markets growth rate, expected growth rate, key growth levers, leading region, top grossing product types, etc. It includes more of a qualitative information about the market.)
6.1. Market Size Forecast Market Size Forecast Market Size Forecast
6.1.1. By Value By Value
6.2. Market Share Forecast Market Share Forecast Market Share Forecast
6.2.1. By Drug Class (Branded v/s Generics)) By Drug Class (Branded v/s Generics)) By Drug Class (Branded v/s Generics))
6.2.1.1. By Branded (Bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), Parathyroid Hormone Therapy, Calcitonin, Rank Ligand Inhibitors, Others) By Branded (Bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), Parathyroid Hormone Therapy, Calcitonin, Rank Ligand Inhibitors, Others)
6.2.2. By Route of Administration (Oral, Injectable, Others) By Route of Administration (Oral, Injectable, Others)
6.2.3. By Osteoporosis Disease Type(Primary Osteoporosis, Secondary Osteoporosis) By Osteoporosis Disease Type(Primary Osteoporosis, Secondary Osteoporosis)
6.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
6.2.5. By Company (2020) By Company (2020)
6.2.6. By Region By Region
6.3. Product Market Map Product Market Map Product Market Map Product Market Map
4

• Table of Contents

S. No. Contents Contents Contents Contents Contents Page No.
7. Asia-Pacific Osteoporosis Drugs Market Outlook Asia-Pacific Osteoporosis Drugs Market Outlook Asia-Pacific Osteoporosis Drugs Market Outlook Asia-Pacific Osteoporosis Drugs Market Outlook Asia-Pacific Osteoporosis Drugs Market Outlook
7.1. Market Size Forecast Market Size Forecast Market Size Forecast Market Size Forecast
7.1.1. By Value By Value By Value
7.2. Market Share Forecast Market Share Forecast Market Share Forecast Market Share Forecast
7.2.1. By Drug Class By Drug Class By Drug Class
7.2.2. By Route of Administration By Route of Administration By Route of Administration
7.2.3. By Osteoporosis Disease Type By Osteoporosis Disease Type By Osteoporosis Disease Type
7.2.4. By Distribution Channel By Distribution Channel By Distribution Channel
7.2.5. By Country By Country By Country
7.3. Asia-Pacific Country Analysis Asia-Pacific Country Analysis Asia-Pacific Country Analysis Asia-Pacific Country Analysis
7.3.1. China Osteoporosis Drugs Market Outlook China Osteoporosis Drugs Market Outlook China Osteoporosis Drugs Market Outlook
7.3.1.1. Market Size Forecast Market Size Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share Forecast Market Share Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Route of Administration
7.3.1.2.3. By Osteoporosis Disease Type
7.3.1.2.4. By Distribution Channel
5

• Table of Contents

S. No. Contents Contents Contents Contents Contents Page No.
7.3.2. India Osteoporosis Drugs Market Outlook India Osteoporosis Drugs Market Outlook India Osteoporosis Drugs Market Outlook
7.3.2.1. Market Size Forecast Market Size Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share Forecast Market Share Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Route of Administration
7.3.2.2.3. By Osteoporosis Disease Type
7.3.2.2.4. By Distribution Channel
7.3.3. Japan Osteoporosis Drugs Market Outlook Japan Osteoporosis Drugs Market Outlook Japan Osteoporosis Drugs Market Outlook
7.3.3.1. Market Size Forecast Market Size Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share Forecast Market Share Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Route of Administration
7.3.3.2.3. By Osteoporosis Disease Type
7.3.3.2.4. By Distribution Channel
6

• Table of Contents

S. No. Contents Contents Contents Contents Contents Page No.
7.3.4. South Korea Osteoporosis Drugs Market Outlook South Korea Osteoporosis Drugs Market Outlook South Korea Osteoporosis Drugs Market Outlook
7.3.4.1. Market Size Forecast Market Size Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share Forecast Market Share Forecast
7.3.4.2.1. By Drug Class
7.3.4.2.2. By Route of Administration
7.3.4.2.3. By Osteoporosis Disease Type
7.3.4.2.4. By Distribution Channel
7.3.5. Australia Osteoporosis Drugs Market Outlook Australia Osteoporosis Drugs Market Outlook Australia Osteoporosis Drugs Market Outlook
7.3.5.1. Market Size Forecast Market Size Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share Forecast Market Share Forecast
7.3.5.2.1. By Drug Class
7.3.5.2.2. By Route of Administration
7.3.5.2.3. By Osteoporosis Disease Type
7.3.5.2.4. By Distribution Channel
7

• Table of Contents

S. No. Contents Contents Contents Contents Contents Page No.
8. Europe Osteoporosis Drugs Market Outlook Europe Osteoporosis Drugs Market Outlook Europe Osteoporosis Drugs Market Outlook Europe Osteoporosis Drugs Market Outlook Europe Osteoporosis Drugs Market Outlook
8.1. Market Size Forecast Market Size Forecast Market Size Forecast Market Size Forecast
8.1.1. By Value By Value By Value
8.2. Market Share Forecast Market Share Forecast Market Share Forecast Market Share Forecast
8.2.1. By Drug Class By Drug Class By Drug Class
8.2.2. By Route of Administration By Route of Administration By Route of Administration
8.2.3. By Osteoporosis Disease Type By Osteoporosis Disease Type By Osteoporosis Disease Type
8.2.4. By Distribution Channel By Distribution Channel By Distribution Channel
8.2.5. By Country By Country By Country
8.3. Europe Country Analysis Europe Country Analysis Europe Country Analysis Europe Country Analysis
8.3.1. France Osteoporosis Drugs Market Outlook France Osteoporosis Drugs Market Outlook France Osteoporosis Drugs Market Outlook
8.3.1.1. Market Size Forecast Market Size Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share Forecast Market Share Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Route of Administration
8.3.1.2.3. By Osteoporosis Disease Type
8.3.1.2.4. By Distribution Channel
8

• Table of Contents

S. No. Contents Contents Contents Contents Contents Page No.
8.3.2. Germany Osteoporosis Drugs Market Outlook Germany Osteoporosis Drugs Market Outlook Germany Osteoporosis Drugs Market Outlook
8.3.2.1. Market Size Forecast Market Size Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share Forecast Market Share Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Route of Administration
8.3.2.2.3. By Osteoporosis Disease Type
8.3.2.2.4. By Distribution Channel
8.3.3. United Kingdom Osteoporosis Drugs Market Outlook United Kingdom Osteoporosis Drugs Market Outlook United Kingdom Osteoporosis Drugs Market Outlook United Kingdom Osteoporosis Drugs Market Outlook
8.3.3.1. Market Size Forecast Market Size Forecast Market Size Forecast
8.3.3.1.1. By Value By Value
8.3.3.2. Market Share Forecast Market Share Forecast Market Share Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Route of Administration
8.3.3.2.3. By Osteoporosis Disease Type
8.3.3.2.4. By Distribution Channel
9

• Table of Contents

S. No. Contents Contents Contents Contents Contents Page No.
8.3.4. Italy Osteoporosis Drugs Market Outlook Italy Osteoporosis Drugs Market Outlook Italy Osteoporosis Drugs Market Outlook
8.3.4.1. Market Size Forecast Market Size Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share Forecast Market Share Forecast
8.3.4.2.1. By Drug Class
8.3.4.2.2. By Route of Administration
8.3.4.2.3. By Osteoporosis Disease Type
8.3.4.2.4. By Distribution Channel
8.3.5. Spain Osteoporosis Drugs Market Outlook Spain Osteoporosis Drugs Market Outlook Spain Osteoporosis Drugs Market Outlook Spain Osteoporosis Drugs Market Outlook
8.3.5.1. Market Size Forecast Market Size Forecast Market Size Forecast
8.3.5.1.1. By Value By Value
8.3.5.2. Market Share Forecast Market Share Forecast Market Share Forecast
8.3.5.2.1. By Drug Class
8.3.5.2.2. By Route of Administration
8.3.5.2.3. By Osteoporosis Disease Type
8.3.5.2.4. By Distribution Channel
10

• Table of Contents

S. No. Contents Contents Contents Contents Contents Page No.
9. North America Osteoporosis Drugs Market Outlook North America Osteoporosis Drugs Market Outlook North America Osteoporosis Drugs Market Outlook North America Osteoporosis Drugs Market Outlook North America Osteoporosis Drugs Market Outlook
9.1. Market Size Forecast Market Size Forecast Market Size Forecast Market Size Forecast
9.1.1. By Value By Value By Value
9.2. Market Share Forecast Market Share Forecast Market Share Forecast Market Share Forecast
9.2.1. By Drug Class By Drug Class By Drug Class
9.2.2. By Route of Administration By Route of Administration By Route of Administration
9.2.3. By Osteoporosis Disease Type By Osteoporosis Disease Type By Osteoporosis Disease Type
9.2.4. By Distribution Channel By Distribution Channel By Distribution Channel
9.2.5. By Country By Country By Country
9.3. North America Country Analysis North America Country Analysis North America Country Analysis North America Country Analysis
9.3.1. United States Osteoporosis Drugs Market Outlook United States Osteoporosis Drugs Market Outlook United States Osteoporosis Drugs Market Outlook
9.3.1.1. Market Size Forecast Market Size Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share Forecast Market Share Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Route of Administration
9.3.1.2.3. By Osteoporosis Disease Type
9.3.1.2.4. By Distribution Channel
11

• Table of Contents

S. No. Contents Contents Contents Contents Contents Page No.
9.3.2. Canada Osteoporosis Drugs Market Outlook Canada Osteoporosis Drugs Market Outlook Canada Osteoporosis Drugs Market Outlook
9.3.2.1. Market Size Forecast Market Size Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share Forecast Market Share Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Route of Administration
9.3.2.2.3. By Osteoporosis Disease Type
9.3.2.2.4. By Distribution Channel
9.3.3. Mexico Osteoporosis Drugs Market Outlook Mexico Osteoporosis Drugs Market Outlook Mexico Osteoporosis Drugs Market Outlook
9.3.3.1. Market Size Forecast Market Size Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share Forecast Market Share Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Route of Administration
9.3.3.2.3. By Osteoporosis Disease Type
9.3.3.2.4. By Distribution Channel
12

• Table of Contents

S. No. Contents Contents Contents Contents Contents Page No.
10. South America Osteoporosis Drugs Market Outlook South America Osteoporosis Drugs Market Outlook South America Osteoporosis Drugs Market Outlook South America Osteoporosis Drugs Market Outlook South America Osteoporosis Drugs Market Outlook
10.1. Market Size Forecast Market Size Forecast Market Size Forecast Market Size Forecast
10.1.1. By Value By Value By Value
10.2. Market Share Forecast Market Share Forecast Market Share Forecast Market Share Forecast
10.2.1. By Drug Class By Drug Class By Drug Class
10.2.2. By Route of Administration By Route of Administration By Route of Administration
10.2.3. By Osteoporosis Disease Type By Osteoporosis Disease Type By Osteoporosis Disease Type
10.2.4. By Distribution Channel By Distribution Channel By Distribution Channel
10.2.5. By Country By Country By Country
10.3. South America Country Analysis South America Country Analysis South America Country Analysis South America Country Analysis
10.3.1. Brazil Osteoporosis Drugs Market Outlook Brazil Osteoporosis Drugs Market Outlook Brazil Osteoporosis Drugs Market Outlook
10.3.1.1. Market Size Forecast Market Size Forecast
10.3.1.1.1 By Value
10.3.1.2. Market Share Forecast Market Share Forecast
10.3.1.2.1. By Drug Class
10.3.1.2.2. By Route of Administration
10.3.1.2.3. By Osteoporosis Disease Type
10.3.1.2.4. By Distribution Channel
13

• Table of Contents

S. No. Contents Contents Contents Contents Contents Page No.
10.3.2. Argentina Osteoporosis Drugs Market Outlook Argentina Osteoporosis Drugs Market Outlook Argentina Osteoporosis Drugs Market Outlook
10.3.2.1. Market Size Forecast Market Size Forecast
10.3.2.1.1 By Value
10.3.2.2. Market Share Forecast Market Share Forecast
10.3.2.2.1. By Drug Class
10.3.2.2.2. By Route of Administration
10.3.2.2.3. By Osteoporosis Disease Type
10.3.2.2.4. By Distribution Channel
10.3.3. Colombia Osteoporosis Drugs Market Outlook Colombia Osteoporosis Drugs Market Outlook Colombia Osteoporosis Drugs Market Outlook
10.3.3.1. Market Size Forecast Market Size Forecast
10.3.3.1.1 By Value
10.3.3.2. Market Share Forecast Market Share Forecast
10.3.3.2.1. By Drug Class
10.3.2.2.2. By Route of Administration
10.3.2.2.3. By Osteoporosis Disease Type
10.3.2.2.4. By Distribution Channel
14

• Table of Contents

S. No. Contents Contents Contents Contents Contents Page No.
11. Middle East Africa Osteoporosis Drugs Market Outlook Middle East Africa Osteoporosis Drugs Market Outlook Middle East Africa Osteoporosis Drugs Market Outlook Middle East Africa Osteoporosis Drugs Market Outlook Middle East Africa Osteoporosis Drugs Market Outlook
11.1. Market Size Forecast Market Size Forecast Market Size Forecast Market Size Forecast
11.1.1. By Value By Value By Value
11.2. Market Share Forecast Market Share Forecast Market Share Forecast Market Share Forecast
11.2.1. By Drug Class By Drug Class By Drug Class
11.2.2. By Route of Administration By Route of Administration By Route of Administration
11.2.3. By Osteoporosis Disease Type By Osteoporosis Disease Type By Osteoporosis Disease Type
11.2.4. By Distribution Channel By Distribution Channel By Distribution Channel
11.2.5. By Country By Country By Country
11.3. Middle East Africa Country Analysis Middle East Africa Country Analysis Middle East Africa Country Analysis Middle East Africa Country Analysis
11.3.1 Saudi Arabia Osteoporosis Drugs Market Outlook Saudi Arabia Osteoporosis Drugs Market Outlook Saudi Arabia Osteoporosis Drugs Market Outlook
11.3.1.1. Market Size Forecast Market Size Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share Forecast Market Share Forecast
11.3.1.2.1. By Drug Class
11.3.1.2.2. By Route of Administration
11.3.1.2.3. By Osteoporosis Disease Type
11.3.1.2.4. By Distribution Channel
15

• Table of Contents

S. No. Contents Contents Contents Contents Contents Page No.
11.3.2. UAE Osteoporosis Drugs Market Outlook UAE Osteoporosis Drugs Market Outlook UAE Osteoporosis Drugs Market Outlook
11.3.2.1. Market Size Forecast Market Size Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share Forecast Market Share Forecast
11.3.2.2.1. By Drug Class
11.3.2.2.2. By Route of Administration
11.3.2.2.3. By Osteoporosis Disease Type
11.3.2.2.4. By Distribution Channel
11.3.3. South Africa Osteoporosis Drugs Market Outlook South Africa Osteoporosis Drugs Market Outlook South Africa Osteoporosis Drugs Market Outlook
11.3.3.1. Market Size Forecast Market Size Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share Forecast Market Share Forecast
11.3.3.2.1. By Drug Class
11.3.3.2.2. By Route of Administration
11.3.3.2.3. By Osteoporosis Disease Type
11.3.3.2.4. By Distribution Channel
16

• Table of Contents

S. No. Contents Contents Contents Contents Contents Page No.
11.3.4. Kuwait Osteoporosis Drugs Market Outlook Kuwait Osteoporosis Drugs Market Outlook Kuwait Osteoporosis Drugs Market Outlook
11.3.4.1. Market Size Forecast Market Size Forecast
11.3.4.1.1. By Value
11.3.4.2. Market Share Forecast Market Share Forecast
11.3.4.2.1. By Drug Class
11.3.4.2.2. By Route of Administration
11.3.4.2.3. By Osteoporosis Disease Type
11.3.4.2.4. By Distribution Channel
12. Market Dynamics Market Dynamics
12.1. Drivers Drivers Drivers
12.2. Challenges Challenges Challenges
13. Market Trends Developments Market Trends Developments Market Trends Developments Market Trends Developments
14. Competitive Landscape Competitive Landscape Competitive Landscape Competitive Landscape
14.1. Competition Outlook Competition Outlook Competition Outlook Competition Outlook
14.2. Company Profiles (SWOT analysis of top 5 players profiled) Company Profiles (SWOT analysis of top 5 players profiled) Company Profiles (SWOT analysis of top 5 players profiled) Company Profiles (SWOT analysis of top 5 players profiled)
14.2.1. Company Details 14.2.1. Company Details 14.2.1. Company Details
14.2.2. Products Services 14.2.2. Products Services 14.2.2. Products Services
14.2.3. Financials (As Reported) 14.2.3. Financials (As Reported) 14.2.3. Financials (As Reported)
14.2.4. Key Market Focus Geographical Presence 14.2.4. Key Market Focus Geographical Presence 14.2.4. Key Market Focus Geographical Presence 14.2.4. Key Market Focus Geographical Presence
14.2.5. Recent Developments 14.2.5. Recent Developments 14.2.5. Recent Developments
14.2.6. Key Management Personnel 14.2.6. Key Management Personnel 14.2.6. Key Management Personnel
15. Strategic Recommendations Strategic Recommendations Strategic Recommendations
16. About Us Disclaimer About Us Disclaimer About Us Disclaimer
17
RESEARCH METHODOLOGY
18

• Research Methodology

Market Profiling
Data Analysis
Data Collection
Data Validation
Developing List of Respondents
Formulating Questionnaire
In-depth secondary research was conducted to
determine top players in the global osteoporosis
drugs market, overall market size and segmental
market size.
The data was scrutinized using MS-Excel,
statistical tools and internal proprietary
database to obtain qualitative and quantitative
insights about the global osteoporosis drugs
market.
Data obtained as a result of primary and
secondary research was validated through rigorous
triangulation.
TechSci conducted interviews with industry
experts and industry players for data collection
and verification.
In order to conduct industry experts interviews,
TechSci formulated a detailed discussion guide.
List of industry players and industry specialists
was developed.
Primary Research
Desk Research
Company Analysis

• Recent Developments
• Market Changing Aspects/Dynamics
• Government Policies
• Conclusion

• Market Participants
• Key Strengths

• Identifying Key Opinion Leaders
• Questionnaire Design
• In-depth Interviews

19

• Research Methodology

• Baseline Methodology
• Our dedicated team of industry experts has
  monitored and analyzed various aspects of the
  global osteoporosis drugs market. The team has
  analyzed the outlook of various segments of this
  market, while considering the major influencing
  factors such as rising awareness among the public
  about osteoporosis care are some key factors
  propelling the market growth. The study includes
  market forecasting, which would enable our
  clients to take better decisions while planning
  their strategy to achieve sustainability in the
  global osteoporosis drugs market.
• Methodology Followed for Calculation of Market
  Size
• Market Size by Value Market size, in terms of
  value, for the year 2020 was calculated based on
  information collected through exhaustive
  secondary research and primary surveys, with
  various key opinion leaders/stakeholders, such as
  osteoporosis drugs companies, channel partners,
  market influencers end users, industry experts,
  and other industry participants.
• The team interviewed more than 15 20
  osteoporosis drugs companies, 100 120 end
  users, and 15 20 industry experts and other
  value chain stakeholders in the global
  osteoporosis drugs market to obtain the overall
  market size from 2016 to 2020, which was
  validated by the Delphi technique. Taking
  standard deviation into consideration, the market
  size was averaged out, to arrive at the market
  size data during 2016-2020.

20

• Research Methodology

• Respondents were asked about the current and
  future market growth rates, market shares by drug
  class, by route of administration, by
  osteoporosis disease type, by distribution
  channel, by company and by region. Removing the
  outlier responses, the geometric mean of growth
  estimates and provider wise revenue shares
  generated across various segments were
  considered, to arrive at the final revenue
  shares. Revenue shares generated across various
  segments were further triangulated from other
  stakeholders.
• Methodology Followed for Calculation of Market
  Shares
• Market shares by drug class, by route of
  administration, by osteoporosis disease type, by
  distribution channel, by company and by region
  were calculated based on the responses received
  through primary surveys with industry experts, in
  which the respondents were asked about the market
  shares or revenue generated from various segments
  of osteoporosis drugs markets. The final shares
  were calculated by taking the geometric mean of
  the responses gathered from key opinion leaders
  after eliminating the outliers.
• Methodology Followed for Forecasting
• TechSci Research performed periodical checks on
  data collected through the surveys with logic
  checks and analyzed the survey results in
  SPSS/Tableau Software.
• Data triangulation techniques were applied to
  fill the gaps and to present a more meaningful
  picture of the market. To forecast global
  osteoporosis drugs market, TechSci Research used
  various forecast techniques such as
• Moving Average
• Time Series Analysis
• Regression Analysis
• Econometric and Judgmental Analysis

21

• Research Methodology

TechSci Research used its own forecast tool,
which is based on the growth of various allied
industries in respective regions. TechSci
Research also used the impact analysis during
short, medium and long term period to estimate
the demand and to reach accurate market numbers.
It should be noted that the figures compiled are
only for the organized market including market
share data. The currency used in the report is
the United States Dollar (USD), with the market
size indicated in USD million.
Partial List of Companies Interviewed Key Secondary Sources
F. Hoffmann-La Roche Ltd Pfizer, Inc. Teva Pharmaceuticals Industries Ltd. Novartis International AG GlaxoSmithKline Plc Merck Co. Inc. Amgen, Inc. Allergan plc Eli Lilly and Company Radius Health, Inc. Sun Pharmaceutical Industries Ltd. Takeda Pharmaceutical Company Limited Sanofi S.A. Abiogen Pharma S.p.A Merrion Pharmaceuticals Plc World Bank TechSci Research Proprietary Database Knowledge Repository Company Annual Reports Industry Magazines Industry Reports News Dailies Credible Paid Databases
22

• Industry Brief

According to TechSci Research report, Global
Osteoporosis Drugs Market By Drug Class
(Bisphosphonates, Selective Estrogen Inhibitors
Modulator (SERM), Parathyroid Hormone Therapy,
Calcitonin, Rank Ligand Inhibitors, and Others),
By Osteoporosis Disease Type (Primary
Osteoporosis, Secondary Osteoporosis), By Route
of Administration (Oral, Injectable, and Others),
By Gender (Female, Male), By Distribution Channel
(Hospital Pharmacies, Retail Pharmacies, Online
Pharmacies), By Region, Forecast Opportunities,
2026, the market is anticipated to grow at a
healthy CAGR during the forecast period. The key
factors propelling the growth of the global
osteoporosis drugs market include rising
prevalence of osteoporosis and surge in geriatric
population around the world as they pose high
susceptibility for osteoporosis. Growing adoption
of sedentary lifestyle is also impacting bone
health and thus, there is a rise in demand for
osteoporosis drugs. Additionally, the increase in
osteoporosis cases due to menopause in women is
acting as a major growth driver for this market.
In men, lifestyle associated factors such as
smoking and alcohol abuse are found to promote
osteoporosis. This is further expected to augment
the global osteoporosis drugs market through
2026. Moreover, increasing investment in RD
activities for the development of advanced new
drug classes is also fueling the market growth.
The wide range of pipeline drugs for approval in
clinical trials are also expected to provide
lucrative growth opportunities for osteoporosis
drug manufacturers. However, the market is also
prone to some challenges. Several side effects of
osteoporosis drugs such as heartburn, nausea,
irritable bowel syndrome and ulcers in the
stomach are likely to hamper the market growth.
Furthermore, the time-taking drug approval
process is also anticipated to restrain the
global osteoporosis drugs market growth. Global
osteoporosis drugs market can be segmented based
on disease type, drug class, route of
administration, gender, distribution channel and
region. Based on drug class, the market can be
segmented into bisphosphonates, Selective
Estrogen Inhibitors Modulator (SERM), parathyroid
hormone therapy, calcitonin, rank ligand
inhibitors, and others. Among them, parathyroid
hormone therapy are expected to register highest
CAGR during the forecast period as they are
increasingly being used to treat osteoporosis and
have lesser side effects. Based on route of
administration, global osteoporosis drugs market
can be segmented into oral, injectable, and
others. Among them, the oral segment accounted
for largest market share in 2020 owing to
abundant availability of medications which are
taken orally. However, the injectable segment is
anticipated to witness fastest growth through
2026 owing to growing need for drugs that exhibit
improved bioavailability rapid mode of
action. Major companies operating in global
osteoporosis drugs market include F. Hoffmann-La
Roche Ltd, Pfizer, Inc., Teva Pharmaceuticals
Industries Ltd., Novartis International AG,
GlaxoSmithKline Plc, Merck Co. Inc., Amgen,
Inc., Allergan plc, Eli Lilly and Company, Radius
Health, Inc., Sun Pharmaceutical Industries Ltd.
and Takeda Pharmaceutical Company Limited, Sanofi
S.A., Abiogen Pharma S.p.A., Merrion
Pharmaceuticals Plc., among others. The companies
are undergoing new product development and
collaborative research initiatives to increase
their share in global osteoporosis drugs
market. North America dominated the global
osteoporosis drugs market in 2020 and is expected
to hold its dominance through 2026 owing to
rising prevalence of osteoporosis and easy
availability of osteoporosis drugs in the region.
However, Asia Pacific is anticipated to undergo
fastest growth during the forecast period due to
thriving life science industry and growing
awareness about the benefits of osteoporosis
drugs, said Mr. Karan Chechi, Research Director
with TechSci Research, a research based global
management consulting firm.
23

• Sample Data - Snapshot

Global Osteoporosis Drugs Market Size, By Value
(USD Million), 2016-2026F
CAGR By Value
CAGR By Value
YY
XX
North America Osteoporosis Drugs Market Share,
By Drug Class, By Value, 20162026F
United States Osteoporosis Drugs Market Share,
By Branded, By Value, 20162026F
24

• Report Ordering

Report Name GLOBAL OSTEOPOROSIS DRUGS
MARKET FORECAST OPPORTUNITIES 2016 2026
License Type Price
Single User License 4900
Multi-User License 5900
Custom Research License 8900
To View Sample OR Purchase Report  
25
About Us Disclaimer
TechSci Research is a global market research and
consulting company with offices in the US, UK and
India. TechSci Research provides market research
reports in number of areas to organizations. The
company uses innovative business models that
focus on improving productivity, while ensuring
creation of high-quality reports. The proprietary
forecasting models use various analyses of both
industry-specific and macroeconomic variables on
a state-by-state basis to produce a unique
bottom-up model of a country, regional and
global industry prospects. Combined with the
detailed analysis of company activity and
industry trends, the result is a uniquely rich
evaluation of the opportunities available in the
market.
Related Reports

• Next Generation Biotherapeutics Market - Global
  Industry Size, Share, Trends, Competition,
  Opportunity and Forecast, Segmented By
  Therapeutic Area (Oncology, Autoimmune/
  Inflammatory Diseases), By Technology
  (Antibody-Drug Conjugates, Bispecific Antibodies,
  Antibody Fragments, Antibody-like Proteins,
  Others), By Region 2016-2026
• United States Blood Glucose Monitoring Devices
  Market By Product (Self Blood Glucose Monitoring
  Devices v/s Continuous Glucose Monitoring
  Devices), By Application (Type 2 Diabetes, Type 1
  Diabetes, Gestational Diabetes), By End User
  (Home Care Settings, Hospital Clinics, Others),
  By Region, Competition Forecast Opportunities,
  2026

TechSci Research North America 708 Third
Avenue, Manhattan, New York, United States Tel
1- 646- 360- 1656 Email sales_at_techsciresearch.co
m www.techsciresearch.com
TechSci Research Europe 54, Old brook,
Bretton, Peterborough, United Kingdom Email
sales_at_techsciresearch.com www.techsciresearch.com
TechSci Research Asia-Pacific B 44, Sector
57, Noida, National Capital Region, U.P. -
India Tel [phone] Email
sales_at_techsciresearch.com www.techsciresearch.com
Disclaimer
The contents of this report are based on
information generally available to the public
from sources believed to be reliable. No
representation is made that it is timely,
accurate or complete. TechSci Research has taken
due care and caution in compilation of data as
this has been obtained from various sources
including which it considers reliable and
firsthand. However, TechSci Research does not
guarantee the accuracy, adequacy or completeness
of any information and it is not responsible for
any errors or omissions or for the results
obtained from the use of such information and
especially states that it has no financial
liability whatsoever to the subscribers / users
of this report. The information herein, together
with all estimates and forecasts, can change
without notice. All the figures provided in this
document are indicative of relative market size
and are strictly for clients internal
consumption. Usage of the same for purpose other
than internal will require prior approval of
TechSci Research.